Ignite Creation Date:
2024-07-17 @ 11:01 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06461689
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-06-05
Brief Title:
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PETCT and 177Lu-PSMA SPECTCT in Metastatic Castration-resistant Prostate Cancer
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Comparison of Changes in Tumor Burden Toral Tumor Volume TMTV and Total Lesion Activity TLA in 68Ga-PSMA-11 PETCT and 177Lu-PSMA SPECTCT in the Monitoring of Metastatic Castration-resistant Prostate Cancer Treated With 177Lutetium-PSMA-617
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PROLUT
Brief Summary:
To demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECTCT versus 68Ga-PSMA-11 PETCT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA
Detailed Description:
Since few years therapy by 177Lu-PSMA in nancy hospital began A lots of datas were collected Prostate cancer is the number one killer in france and this is very important to find a diagnostic tool
The hypothesis of this study is to demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECTCT versus 68Ga-PSMA-11 PETCT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA
The hypothesis of this study is to demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECTCT versus 68Ga-PSMA-11 PETCT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None